Latest news with #Colitis
The Irish Sun
8 hours ago
- Entertainment
- The Irish Sun
New Love Island bombshell Toni reveals crippling health battle that saw her rushed to hospital
LOVE Island bombshell Toni Laites has opened about her chronic health condition ahead of entering the villa. The Advertisement 6 Toni has shared her health battle with ulcerative colitis Credit: Shutterstock Editorial 6 When she was 17, doctors looked after her to make sure she got to prom Credit: Instagram/@connecticutchildrens 6 Toni thanked the doctors for making her prom dream come true Credit: Instagram/@connecticutchildrens But ahead of entering the villa, Toni shared that she is also battling an illness that leaves her in agonising pain. She said ahead of entering the show: "I have "They told me, 'You can't go' and then they said, 'Surprise, you're going to prom!' "Nothing that exciting happens in Connecticut, so it was a big deal and a few articles were written about me." Advertisement READ MORE LOVE ISLAND "What I hope people see from me being on Love Island is that not all illnesses are visible," she added. "It doesn't have to hold you back, you can travel etc…I live my life day-to-day like anyone else." In 2018, Toni was taken to prom straight from the hospital at Connecticut Children's Medical Center, with the team looking after her making sure she was primped and primed for the event. She wrote a gold sequinned mermaid gown for the event, and posed with her doctors before going. Advertisement Most read in Love Island Exclusive Exclusive Exclusive The hospital later shared photos of her getting ready on Instagram, writing: " After spending a week inpatient for a flare up of #UlcerativeColitis , 17-year old Toni Laites of Newington was told she would be unable to attend her her team of doctors and nurses at Connecticut Children's banded together to grant her a therapeutic leave, giving Toni the opportunity to experience the Cinderella prom she always dreamed of. " Toni has said she's entering the Love Island UK villa because dating in the States is "a mess" – particularly after moving from Connecticut to Florida and then Las Vegas, Nevada. Love rats & machete arrests: Love Island's most DRAMATIC launch ever?! "I live in cities that are fast-paced and party places; Las Vegas and Florida," she explained. "People are here for a good time, not a long time. I live in Sin City! Advertisement "I do love Las Vegas. I've met some of the greatest people I've ever met there. I'm willing to relocate, it would just break my heart to not have my job anymore." She warns that her "icks" are bad breath, bad hygiene, and not being dressing appropriately for a date. Toni will enter the house this week, with the series kicking off on Monday night with Love Island starts Monday at 9pm on ITV, ITV2 and ITVX. Advertisement What is Ulcerative Colitis? Here's what you need to know about Ulcerative Colitis.. Colitis is a condition where the colon and rectum become inflamed. The colon is the large intestine, or bowel, and the rectum is the end of the bowel where stools are stored. Ulcers can develop on the colon's lining and bleed and produce pus. Ulcerative colitis is a form of colitis that is caused by autoimmune inflammation (the body attacking itself), whereas colitis can be caused by a number of factors including infection. Ulcerative colitis is similar to another condition which causes inflammation of the gut - Crohn's disease. Symptoms can often be very mild for weeks or months but flare ups with extreme symptoms can cause a lot of pain and trouble for sufferers. Find out 6 Despite being told she couldn't go after a flare up, the doctors made it happen for her Credit: Instagram/@connecticutchildrens 6 The star looked incredible as she made it to the event Credit: Instagram/@ctvarsity 6 Despite her illness, Toni glammed up in time for the event Credit: Instagram/@mariella_creations
Glasgow Times
19-05-2025
- Entertainment
- Glasgow Times
Glasgow portaloo at SWG3 brings IBD into the spotlight
But not for the usual reasons—this one has been transformed into a powerful awareness campaign for inflammatory bowel disease (IBD). Launched by the Catherine McEwan Foundation in partnership with creative agency MadeBrave, the installation marks World IBD Day on May 19 and aims to spotlight what life is really like for the thousands of Scots living with IBD. READ MORE: Disco diva stuns fans with surprise appearance at huge Hydro gig From the outside, it looks like your average portaloo. But step inside, and you're met with an entirely different experience: a cinema-style seat, walls covered in eye-opening facts, and a short film featuring heartfelt messages from DJ George Bowie, Callum Beattie, Robyn Red, and Starsailor. Callum Beattie puts it plainly in the video, saying: 'Do you know what really sucks? There are people who want to be at the festival but they're stuck inside yet again. "Not because they didn't want to be at the festival, but because of Crohn's and Colitis — their body just says no.' (Image: Supplied) IBD, which includes Crohn's disease and ulcerative colitis, affects more than 1 in 100 people in Scotland, with symptoms ranging from chronic pain and fatigue to anxiety and the need for long-term treatment or surgery. Despite its prevalence, it remains widely misunderstood. Charity founder Derek McEwan, who set up the Foundation in memory of his mum Catherine, said the installation is designed to get people thinking differently. READ MORE: 'Wildly excited': Date revealed for award-winning musical's Glasgow premiere He said: 'IBD is a battle for those who live with it, as their families. 'My mum lived with severe Crohn's for most of her life. I grew up in waiting rooms. She never once complained, but I saw how hard it was. 'Even things that are meant to be fun, like going to a music festival, can become a source of stress. Many people with IBD just don't go. "The fear of flare-ups, access to toilets, and the planning is exhausting. 'We created this space to help people stop, think, and understand. For some, a festival loo is something to avoid. "For others, it's the reason they miss out entirely.' The campaign follows last year's headline-grabbing giant toilet roll billboard in Glasgow and continues the Foundation's mission to challenge stigma, fund research, and support those affected across Scotland. Want to help? Visit or text IBD to 70085 to donate £5.
Globe and Mail
11-04-2025
- Health
- Globe and Mail
Ulcerative Colitis Market Set for Robust Growth Across the 7MM from USD 8.4 Billion in 2023
Key Ulcerative Colitis companies in the market include - Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck and Mesoblast, among others. The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions by companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck and Mesoblast, among others. DelveInsight's " Ulcerative Colitis Market Insight, Epidemiology And Market Forecast - 2034" report delivers comprehensive insights into the ulcerative colitis market dynamics, epidemiological trends, and treatment landscape across the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The ulcerative colitis market size in the 7MM was USD 8.4 billion in 2023, with the United States accounting for the largest share at USD 5.9 billion. This market is poised for significant growth during the forecast period (2024-2034), driven by improved drug uptake, increased disease awareness, and a robust pipeline of innovative therapies. Download the Ulcerative Colitis market report to understand which factors are driving the Ulcerative Colitis therapeutic market @ Ulcerative Colitis Market Trends The report also provides a detailed epidemiological analysis and forecasts up to 2034, segmented by Total Diagnosed Prevalent Cases of Ulcerative Colitis, Age-specific Cases of Ulcerative Colitis, Severity-specific Cases of Ulcerative Colitis, and Total Treated Patients of Ulcerative Colitis. According to the latest epidemiological analysis, the total diagnosed prevalent cases of ulcerative colitis in the 7MM comprised approximately 3 Million in 2023, with projections indicating continued growth through 2034. The United States contributed the largest share, with approximately 47% of the diagnosed prevalent population, while Germany and Japan each accounted for roughly 10% of the total 7MM patient pool. When examining disease severity, approximately 521K mild cases and 860K moderate to severe cases were identified across these markets. The ulcerative colitis treatment market currently encompasses multiple therapeutic approaches, including aminosalicylates, corticosteroids, immunomodulators, biologic therapies, S1P modulators, and Janus kinase inhibitors. Anti-TNF alpha agents remain the recommended first-line treatment option for many patients. Among the currently approved therapies, HUMIRA (AbbVie), REMICADE (Janssen Pharmaceuticals), SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda Pharmaceuticals), XELJANZ (Pfizer), STELARA (Janssen Pharmaceuticals), CAROGRA (EA Pharma/Kissei Pharma), JYSELECA (Gilead Sciences and Galapagos NV), OMVOH (Eli Lilly), SKYRIZI (AbbVie/Boehringer Ingelheim), RINVOQ (AbbVie), and ZEPOSIA (Bristol-Myers Squibb), among others have established strong market positions. By 2034, ENTYVIO is projected to generate the highest revenue in the United States, followed by HUMIRA (AbbVie). In December 2024, Biocon Biologics and Celltrion received FDA approval for their respective biosimilars to STELARA (Janssen Pharmaceuticals) – YESINTEK (Biocon Biologics) and STEQEYMA (Celltrion) – expanding treatment options for patients with ulcerative colitis. In February 2024, the European Commission granted marketing authorization for VELSIPITY (etrasimod) for patients 16 years and older with moderately to severely active ulcerative colitis following its FDA approval in October 2023. The ulcerative colitis therapeutics market is witnessing significant innovation with several emerging therapies such as, Etrasimod (Arena Pharmaceuticals/Pfizer), ABX464 (Abivax), SHR0302 (Reistone Biopharma), Cobitolimod (InDex Pharmaceuticals), TREMFYA (Janssen Pharmaceuticals), BT-11 (Landos Biopharma/NImmune), PRA023 (Merck), Remestemcel-L (Mesoblast), PF-06651600 (Pfizer) and PF-06700841 (Pfizer) among others. Know which Ulcerative Colitis drug is expected to capture the largest market share in 7MM by 2034. Visit the Ulcerative Colitis Insights Recent developments have further enriched the ulcerative colitis market with several regulatory approvals and clinical advancements. In December 2024, Accropeutics Inc. announced FDA clearance for a Phase II trial of its RIPK2 inhibitor, AC-101, for moderate-to-severe Ulcerative Colitis. Additionally, in November 2024, Johnson & Johnson submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of TREMFYA (guselkumab). In late 2024, AbbVie's SKYRIZI had rapidly outpaced Eli Lilly's OMVOH in the ulcerative colitis market, securing over double the market share just two months post-launch. In January 2025, the FDA granted investigational new drug (IND) clearance for R-5780 (Rise Therapeutics). This innovative therapy leverages gut-regulated immune pathways to enhance the efficacy of immune checkpoint inhibitors, offering a novel approach to treating cancers that are refractory or unresponsive to these therapies. Looking ahead, the ulcerative colitis market is expected to witness significant transformation with the introduction of novel therapeutic classes, including toll-like receptor 9 activators, miR-124 enhancers, and T-cell therapies. While high therapy costs and complications pose challenges, rising awareness, early screening, and advanced treatment strategies are fueling ulcerative colitis treatment market growth. The ulcerative colitis epidemiology and the market landscape present both opportunities and challenges for stakeholders. As treatment paradigms continue to evolve, focusing on personalized medicine and improved patient outcomes, the ulcerative colitis treatment market is positioned for substantial growth, offering new hope for the millions affected by this chronic inflammatory condition worldwide. Table of Contents 1. Key Insights 2. Report Introduction 3. Ulcerative Colitis Market Overview at a Glance 4. Epidemiology and Market Methodology 5. Ulcerative Colitis Executive Summary 6. Ulcerative Colitis Market Disease Background and Overview 7. Ulcerative Colitis Epidemiology and Patient Population 8. Patient Journey 9. Ulcerative Colitis Marketed Therapies 10. Ulcerative Colitis Emerging Drugs 11. Ulcerative Colitis: The 7MM Analysis 12. Ulcerative Colitis Market Access and Reimbursement 13. Ulcerative Colitis KOL Views 14. Ulcerative Colitis SWOT Analysis 15. Ulcerative Colitis Unmet Needs 16. Appendix 17. DelveInsight Capabilities 18. Disclaimer Related Reports Ulcerative Colitis Pipeline Insight Ulcerative Colitis Pipeline Insight provides comprehensive insights about the Ulcerative Colitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Ulcerative Colitis manufacturers, including Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, and Palatin Technologies, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Globe and Mail
07-04-2025
- Health
- Globe and Mail
Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Ulcerative Colitis Pipeline Insight 2025' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook Key Takeaways from the Ulcerative Colitis Pipeline Report In April 2025, Merck Sharp & Dohme LLC announced a study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12. In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC). DelveInsight's Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment. The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others. Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment Ulcerative Colitis Emerging Drugs Profile Obefazimod: Abivax Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis. ABBV-668: AbbVie ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis. TEV-48574: Teva Pharmaceutical Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis. SOR102: Sorriso Pharmaceuticals SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis. The Ulcerative Colitis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment. Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs Ulcerative Colitis Companies Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Ulcerative Colitis Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives Scope of the Ulcerative Colitis Pipeline Report Coverage- Global Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others. Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III "Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies Table of Content Introduction Executive Summary Ulcerative Colitis: Overview Pipeline Therapeutics Therapeutic Assessment Ulcerative Colitis– DelveInsight's Analytical Perspective In-depth Commercial Assessment Ulcerative Colitis Collaboration Deals Late Stage Products (Preregistration) Mirikizumab: Eli Lilly and Company Drug profiles in the detailed report….. Late Stage Products (Phase III) Obefazimod: Abivax Drug profiles in the detailed report….. Mid Stage Products (Phase II) ABBV-668: AbbVie Drug profiles in the detailed report….. Early Stage Products (Phase I) SOR102: Sorriso Pharmaceuticals Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Ulcerative Colitis Key Companies Ulcerative Colitis Key Products Ulcerative Colitis- Unmet Needs Ulcerative Colitis- Market Drivers and Barriers Ulcerative Colitis- Future Perspectives and Conclusion Ulcerative Colitis Analyst Views Ulcerative Colitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Sky News
18-02-2025
- Entertainment
- Sky News
Strictly's Amy Dowden awarded MBE by King in 'really surreal' experience
Strictly Come Dancing star Amy Dowden has been awarded an MBE by the King at Buckingham Palace. The 34-year-old, who has Crohn's disease, was honoured for her services to fundraising and raising awareness of inflammatory bowel disease. The Welsh professional dancer, who joined the show in 2017, revealed in 2019 she was living with Crohn's and spoke about her struggles living with the condition in a BBC documentary. On Tuesday, Dowden said being honoured "hasn't sunk in yet" and that she was determined to continue her work raising awareness and funds for Crohn's and colitis. She also said being made a Member of the Order of the British Empire (MBE) was "really surreal" and "like an out-of-body experience". Last year, she was taken to hospital following a Crohn's flare-up while filming the dancing show. Dowden was diagnosed with breast cancer in 2023, shortly after returning from her honeymoon with husband Ben Jones. She said she had spoken to the King about her recovery from cancer as well as the "impact of chemotherapy on my body". The Royal Family has also publicly shared their cancer experiences, with Buckingham Palace announcing last year that Charles has been treated for cancer while the Princess of Wales revealed she was in remission from the disease in January after undergoing chemotherapy. Trademark sparkle Marianne Radcliffe, chief executive of Crohn's & Colitis UK, said: "People never used to talk about Crohn's or Colitis, but Amy has really helped to normalise conversations about these conditions by being open and honest, and adding some of her trademark sparkle. "Every year, 25,000 people in the UK are told they have inflammatory bowel disease, and there will be many who feel less afraid about what lies ahead because of her work." Meanwhile, composer John Rutter, 79, was awarded a knighthood for services to music. Sir John is best known for his choral compositions - including Christmas carols, anthems and extended works - including the Gloria, the Magnificat, and the Requiem. He has been commissioned for several major royal events, including Queen Elizabeth II's golden jubilee; Prince William and Kate's royal wedding in 2011 and King Charles' coronation. Another recipient honoured on Tuesday was Jasvinder Sanghera, who was made a Dame Commander for services to the victims of child, forced marriage and honour-based abuse. Dame Jasvinder was 14-year-old when she was faced with the prospect of a forced marriage. After leaving home, she went on to establish the Karma Nirvana charity in 1993, described on its website as the "first specialist charity for victims and survivors".
